Across the 13 anatomic sites, 5,106 eligible primary carcinomas were evaluated for CDH1 and 7,578 eligible primary carcinomas were evaluated for CTNNB1. All carcinomas evaluated for CDH1 were also evaluated for CTNNB1. For each anatomic site, the number of carcinomas evaluated for CDH1 is given in Figure 1 and the number of carcinomas evaluated for CTNNB1 is given in Figure 2. This evidence concerns the gene CDH1 and carcinoma.